BioSpace News Archive

SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2024 and provides a business update.

Curis, Inc., a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, announced updated data from the ongoing TakeAim Leukemia study in relapsed/refractory AML to be presented at the ASCO and EHA conferences.

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2024.

BeiGene, Ltd., a global oncology company, announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain, June 13-16, 2024.

Gossamer Bio, Inc. will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.

Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, announced its FUTURES National Conference will be held from May 23-26 in Orlando

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments.

During a late-breaking abstract presentation at the annual 2024 NKF Spring Clinical Meetings tomorrow Dr. Dana Rizk, from the University of Alabama at Birmingham Medical Center, will present data on the impact and safety of Fabhalta in the treatment of patients with IgA nephropathy also known as Berger disease.

Incyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA2024) Congress held on June 13-16 in Madrid, Spain, and virtually.